|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
|
ATE454161T1
(de)
*
|
1997-07-18 |
2010-01-15 |
Novo Nordisk Healthcare Ag |
Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
|
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6747003B1
(en)
*
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6693075B1
(en)
*
|
1997-10-23 |
2004-02-17 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6406488B1
(en)
*
|
1998-08-27 |
2002-06-18 |
Heartstent Corporation |
Healing transmyocardial implant
|
|
EP0987274A1
(en)
|
1998-09-15 |
2000-03-22 |
Hoechst Marion Roussel Deutschland GmbH |
Factor VIIa Inhibitors
|
|
EP1059302A1
(en)
|
1999-06-08 |
2000-12-13 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitors
|
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1095933A1
(en)
|
1999-10-30 |
2001-05-02 |
Aventis Pharma Deutschland GmbH |
Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
|
|
CA2739933A1
(en)
*
|
2000-02-11 |
2001-08-16 |
Bayer Healthcare Llc |
Factor vii or viia-like molecules
|
|
EP1278767A4
(en)
|
2000-04-12 |
2003-11-12 |
Principia Pharmaceutical Corp |
ALBUMIN FUSED PROTEINS
|
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
EP1162194A1
(en)
|
2000-06-06 |
2001-12-12 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
|
|
AU2001269803A1
(en)
*
|
2000-06-20 |
2002-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
|
US7160540B2
(en)
*
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
|
US20030211094A1
(en)
*
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
RU2003120070A
(ru)
|
2000-12-06 |
2004-12-27 |
Авентис Фармаа Дойчланд Гмбх (De) |
Производные гуанидина и амидина в качестве ингибиторов фактора ха
|
|
US6825323B2
(en)
*
|
2001-01-10 |
2004-11-30 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
|
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
|
IL157842A0
(en)
*
|
2001-03-22 |
2004-03-28 |
Novo Nordisk Healthcare Ag |
Coagulation factor vii derivatives
|
|
CN1522151A
(zh)
*
|
2001-05-02 |
2004-08-18 |
ŵ��Ų�ڿ˹�˾ |
经修饰的fvii用于治疗ards
|
|
EP1270551A1
(en)
|
2001-06-26 |
2003-01-02 |
Aventis Pharma Deutschland GmbH |
Urea derivatives with antiproteolytic activity
|
|
WO2003022122A2
(en)
*
|
2001-09-10 |
2003-03-20 |
Florence Medical Ltd. |
Individual ffr determination for lesions of a multi-lesioned blood vessel
|
|
ES2556338T3
(es)
|
2001-10-10 |
2016-01-15 |
Novo Nordisk A/S |
Remodelación y glicoconjugación de péptidos
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
WO2003037361A2
(en)
*
|
2001-11-02 |
2003-05-08 |
Novo Nordisk Health Care Ag |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
ES2325653T3
(es)
*
|
2001-12-21 |
2009-09-11 |
Novo Nordisk Health Care Ag |
Composicion liquida de polipeptidos del factor vii.
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
AU2002351755A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Novo Nordisk A/S |
Liquid composition of modified factor vii polypeptides
|
|
CN1665925A
(zh)
*
|
2002-04-30 |
2005-09-07 |
马克西根控股公司 |
凝血因子Ⅶ或Ⅶa多肽变体
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
WO2003092731A1
(en)
*
|
2002-05-03 |
2003-11-13 |
Novo Nordisk A/S |
Stabilised solid compositions of modified factor vii
|
|
BRPI0311959B8
(pt)
*
|
2002-06-21 |
2021-05-25 |
Novo Nordisk Healthcare Ag |
composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
|
|
US20060166874A1
(en)
*
|
2002-09-30 |
2006-07-27 |
Haaning Jesper M |
Fvii or fviia variants having increased clotting activity
|
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
|
US20040176704A1
(en)
*
|
2003-03-04 |
2004-09-09 |
Stevens Timothy A |
Collection device adapted to accept cartridge for point of care system
|
|
EP1605968A2
(en)
*
|
2003-03-18 |
2005-12-21 |
Novo Nordisk Health Care AG |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
|
DE602004021099D1
(de)
*
|
2003-03-20 |
2009-06-25 |
Bayer Healthcare Llc |
Fvii oder fviia varianten
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
|
US20040202726A1
(en)
*
|
2003-04-10 |
2004-10-14 |
Deshay Samuel L. |
Topical blood pressure composition
|
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
|
EP1479680A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
|
EP1479675A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Indazole-derivatives as factor Xa inhibitors
|
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
|
WO2004103398A1
(en)
*
|
2003-05-23 |
2004-12-02 |
Novo Nordisk Health Care Ag |
Protein stabilization in solution
|
|
US7029675B1
(en)
*
|
2003-06-04 |
2006-04-18 |
Shu-Wha Lin |
Hepsin antagonist and methods of use
|
|
CN1839203B
(zh)
*
|
2003-06-19 |
2011-11-16 |
拜耳医药保健有限公司 |
因子VII或VIIa的GLA结构域变体
|
|
ES2382157T3
(es)
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
|
WO2005002615A1
(en)
*
|
2003-07-01 |
2005-01-13 |
Novo Nordisk Health Care Ag |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
KR101293503B1
(ko)
|
2003-08-14 |
2013-08-07 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
KR20130026498A
(ko)
*
|
2003-12-19 |
2013-03-13 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
WO2006035058A2
(en)
*
|
2004-09-29 |
2006-04-06 |
Novo Nordisk Health Care Ag |
Purification of a drug substance of a factor vii polypeptide by removal of desgla-factor vii polypeptide structures
|
|
US20080176790A1
(en)
|
2004-10-29 |
2008-07-24 |
Defrees Shawn |
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
|
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
US20080248959A1
(en)
|
2006-07-21 |
2008-10-09 |
Neose Technologies, Inc. |
Glycosylation of peptides via o-linked glycosylation sequences
|
|
WO2008057683A2
(en)
|
2006-10-03 |
2008-05-15 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
AU2008237411B2
(en)
|
2007-04-03 |
2013-10-03 |
Ratiopharm Gmbh |
Methods of treatment using glycopegylated G-CSF
|
|
MX2009013259A
(es)
|
2007-06-12 |
2010-01-25 |
Novo Nordisk As |
Proceso mejorado para la produccion de azucares de nucleotidos.
|
|
EP2626079A3
(en)
|
2008-02-27 |
2014-03-05 |
Novo Nordisk A/S |
Conjungated factor VIII molecules
|
|
US8450275B2
(en)
|
2010-03-19 |
2013-05-28 |
Baxter International Inc. |
TFPI inhibitors and methods of use
|
|
CN104984319B
(zh)
|
2008-12-19 |
2025-05-09 |
武田药品工业株式会社 |
Tfpi抑制剂和使用方法
|
|
JP5813641B2
(ja)
|
2009-08-24 |
2015-11-17 |
アムニクス オペレーティング インコーポレイテッド |
凝固第ｉｘ因子組成物ならびにそれを製造および使用する方法
|
|
KR101294351B1
(ko)
*
|
2010-05-27 |
2013-08-07 |
동국대학교 산학협력단 |
뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
|
|
EP3564260B1
(en)
|
2012-02-15 |
2022-10-19 |
Bioverativ Therapeutics Inc. |
Factor viii compositions and methods of making and using same
|
|
SI2822577T1
(sl)
|
2012-02-15 |
2019-07-31 |
Bioverativ Therapeutics Inc. |
Rekombinantni proteini faktorja VIII
|
|
JP2015514070A
(ja)
|
2012-03-21 |
2015-05-18 |
バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ |
Ｔｆｐｉ阻害剤および使用方法
|
|
WO2015023891A2
(en)
|
2013-08-14 |
2015-02-19 |
Biogen Idec Ma Inc. |
Factor viii-xten fusions and uses thereof
|
|
JP2018524391A
(ja)
*
|
2015-07-22 |
2018-08-30 |
アイコニック セラピューティクス， インコーポレイテッド |
血管形成および血管新生に付随する障害を処置するための方法
|
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
|
|
WO2017121436A1
(en)
|
2016-01-15 |
2017-07-20 |
Rigshospitalet |
Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
|
|
WO2018091058A1
(en)
|
2016-11-17 |
2018-05-24 |
Rigshospitalet |
177-lu labeled active site inhibited factor vii
|
|
AU2017366709A1
(en)
|
2016-12-02 |
2019-07-18 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
TW202015723A
(zh)
|
2018-05-18 |
2020-05-01 |
美商百歐維拉提夫治療公司 |
治療ａ型血友病的方法
|